[{"address1": "75 State Street", "address2": "Suite 100", "city": "Boston", "state": "MA", "zip": "02109", "country": "United States", "phone": "617 229 6499", "website": "https://www.finchtherapeutics.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.", "fullTimeEmployees": 1, "companyOfficers": [{"maxAge": 1, "name": "Mr. Matthew P. Blischak J.D.", "age": 60, "title": "President, Secretary & CEO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 558807, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lance  Thibault CPA", "age": 57, "title": "Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 168788, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James S. Sigler MBA", "age": 62, "title": "Executive Vice President of CMC", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.5, "open": 1.35, "dayLow": 1.35, "dayHigh": 1.44, "regularMarketPreviousClose": 1.5, "regularMarketOpen": 1.35, "regularMarketDayLow": 1.35, "regularMarketDayHigh": 1.44, "beta": 0.264, "forwardPE": -0.069936864, "volume": 600, "regularMarketVolume": 600, "averageVolume": 62715, "averageVolume10days": 5920, "averageDailyVolume10Day": 5920, "bid": 1.44, "ask": 1.48, "askSize": 40000, "marketCap": 2312294, "fiftyTwoWeekLow": 0.8, "fiftyTwoWeekHigh": 9.483, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 1.96948, "twoHundredDayAverage": 3.29276, "currency": "USD", "enterpriseValue": 11113299, "floatShares": 891857, "sharesOutstanding": 1605760, "sharesShort": 19195, "sharesShortPriorMonth": 10600, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.012, "heldPercentInsiders": 0.53457, "heldPercentInstitutions": 0.113529995, "shortRatio": 0.19, "shortPercentOfFloat": 0.0276, "bookValue": 11.856, "priceToBook": 0.121457495, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -16283000, "trailingEps": -9.81, "forwardEps": -20.59, "enterpriseToEbitda": -0.495, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "FNCH", "underlyingSymbol": "FNCH", "shortName": "Finch Therapeutics Group, Inc.", "longName": "Finch Therapeutics Group, Inc.", "firstTradeDateEpochUtc": 1616160600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b8e86349-7dce-3756-a76c-43df24d3f738", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.44, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 20762000, "totalCashPerShare": 12.93, "ebitda": -22464000, "totalDebt": 29563000, "quickRatio": 5.934, "currentRatio": 6.052, "debtToEquity": 155.284, "returnOnAssets": -0.21935, "returnOnEquity": -0.62639, "freeCashflow": -20337500, "operatingCashflow": -22486000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-15"}]